Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
Melanoma patients given Tecemotide alongside immunotherapy drug Keytruda were 49 per cent more likely to be alive three years later compared to those taking Keytruda alone.
In the longest study yet, melanoma patients given the personalised vaccine alongside the immunotherapy drug Keytruda were half more likely to be alive three years later.